Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2021-04-29 Declaration of Voting R…
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
PHARMANUTRA Synthetic report on voting results shareholder's meeting 26 04 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states it is a "Synthetic Report on voting results" from an "ORDINARY SHAREHOLDERS' MEETING HELD ON APRIL 26, 2021". It details the results (Votes in favour, Votes against, Abstentions) for several agenda items, including financial statement approval and remuneration policy. This content directly corresponds to the definition of reporting official results from a shareholder vote, which maps to the Declaration of Voting Results & Voting Rights Announcements (DVA). It is not the AGM presentation (AGM-R) itself, but the formal results summary.
2021-04-29 English
PHARMANUTRA Rendiconto sintetico delle votazioni assemblea 26 04 2021
AGM Information Classification · 1% confidence The document is titled "ASSEMBLEA ORDINARIA DEL 26 APRILE 2021" (Ordinary General Meeting of April 26, 2021) and contains a "Rendiconto sintetico delle votazioni" (Summary report of the votes). It details the voting results for various resolutions, including the approval of the 2020 Financial Statements (Punto 1.1), allocation of profit (Punto 1.2), remuneration policy (Punto 2.1), and authorization for share buybacks (Punto 3). This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2021-04-29 Italian
PR - PHARMANUTRA Shareholders meeting 26 04 2021
AGM Information Classification · 1% confidence The document is an official announcement (indicated by 'Informazione Regolamentata' and the date/time stamp) detailing the resolutions passed during the Ordinary Shareholders' Meeting held on April 26, 2021. Key items approved include the financial statements for the year ended December 31, 2020, the remuneration report, and authorization for treasury stock transactions. Since the document explicitly reports the *results* and *decisions* made at the Annual General Meeting (AGM), it directly relates to AGM activities. While it mentions the approval of financial statements (which might suggest 10-K or IR), the primary context and subject ('PR - PHARMANUTRA Shareholders meeting 26 04 2021') point to the meeting itself. Therefore, the most appropriate classification is AGM Information (AGM-R).
2021-04-26 English
CS - PHARMANUTRA Assemblea degli azionisti del 26 04 2021
AGM Information Classification · 1% confidence The document is a formal communication from Pharmanutra S.p.A. dated April 26, 2021, regarding the Ordinary Shareholders' Meeting held on the same day. The key resolutions approved include the 2020 financial statements, the distribution of a dividend (€0.67 per share), approval of the remuneration policy, and authorization for share buybacks. The text explicitly mentions the approval of the 'bilancio di esercizio al 31 dicembre 2020' (financial statements for the year ended December 31, 2020) and the dividend distribution. Since this is a summary announcement detailing the outcomes of the AGM, and it specifically covers the approval of the annual financial results and dividend, it strongly relates to both the Annual General Meeting (AGM-R) and the dividend announcement (DIV). However, the primary context is the meeting itself where these key corporate actions were decided and announced. Furthermore, it mentions the approval of the remuneration policy, which is related to DEF 14A, but the overall context is the AGM outcome. Given the title 'ASSEMBLEA ORDINARIA DEGLI AZIONISTI' (Ordinary Shareholders' Meeting) and the comprehensive list of resolutions passed, AGM-R is the most fitting primary classification. The dividend details are a key outcome, but the document is reporting the meeting's results.
2021-04-26 Italian
PR - PHARMANUTRA - new Sideral Med launch
Environmental & Social Information Classification · 1% confidence The document is a press release (indicated by the structure, the subject 'launch', and the content announcing a new product launch: 'PHARMANUTRA S.P.A. LAUNCHES ITS NEW SIDERAL® MED'). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement about a business event (product launch) intended for the market and investors. Since there is no specific category for a general product launch announcement, and it is not a transcript (CT), management discussion (MDA), or a formal financial report, the most appropriate general category for a non-standard, market-facing announcement is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory/market communications that don't fit elsewhere, especially when issued via a regulated information service ('Informazione Regolamentata'). However, given the nature of the announcement (a product launch press release), it often falls under general corporate news. Since RNS is the designated fallback for miscellaneous regulatory announcements, and this is a formal communication disseminated through a regulated channel, RNS is the best fit among the provided options, although 'RPA' (Report Publication Announcement) is sometimes used for press releases announcing reports, this is announcing a product, not a report. Therefore, RNS is chosen as the best fit for a general, non-financial, regulated corporate announcement.
2021-04-19 English
CS - PHARMANUTRA Lancio Sideral Med
Regulatory Filings Classification · 1% confidence The document is an official communication identified by the header "Informazione Regolamentata n. 20106-19-2021" and received on "19 Aprile 2021". The subject is the launch of a new product, SiderAL® Med, by Pharmanutra S.p.A. This type of announcement, detailing a significant business event (product launch) that is material to investors but is not a full financial report (like 10-K or IR) or a specific regulatory filing like insider trading or dividend notice, typically falls under general regulatory announcements or press releases. Given the options, this is a specific business update. It is too detailed to be a simple Report Publication Announcement (RPA) which usually just points to an attached report. It is not a Call Transcript (CT), Earnings Release (ER), or a formal financial report (10-K, IR). Since it is a formal, time-stamped regulatory disclosure about a business development, and it doesn't fit the highly specific categories like DIRS, DIV, or CAP, the most appropriate general category for significant, non-standard corporate news released via regulatory channels is Regulatory Filings (RNS), which serves as a broad category for official company announcements not covered elsewhere. However, looking closely at the content, it is a press release announcing a new product launch and market entry into the 'Alimenti a Fini Medici Speciali' (Special Medical Purpose Foods) sector. While RNS is a fallback, this is a very specific type of corporate news. Since there is no specific category for 'Product Launch Announcement', RNS is the best fit as a general regulatory disclosure.
2021-04-19 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.